Displaying drugs 501 - 525 of 8253 in total
Glucagon
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]
Glucagon was granted FDA...
Approved
Matched Description: … , stimulating glycogenolysis and the release of glucose. ... amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of ... [L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors …
Midodrine
An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.
Approved
Matched Description: … It is used as a vasoconstrictor agent in the treatment of hypotension. …
Meclizine
Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in...
Approved
Matched Description: … It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular …
Eprosartan
Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.
Approved
Matched Description: … By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs …
Prednisone
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone was granted FDA approval on 21 February 1955.
Approved
Vet approved
Omega-3-carboxylic acids
The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl...
Approved
Investigational
Matched Description: … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components ... bioavailability in the treatment of dyslipidemia. ... acid as the most abundant species found in a proportion of 55% and 20% respectively. …
Curcumin
Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and...
Approved
Investigational
Matched Description: … Curcumin is under investigation for the treatment and supportive care of various clinical conditions ... Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical ... rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of …
Ceforanide
Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to...
Approved
Matched Description: … Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic ... Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of …
Gemeprost
Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy . It is not FDA-approved but available in...
Approved
Withdrawn
Matched Description: … Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the ... suppositories and also used in combination with the antiprogestin and mifepristone for termination of …
Phenyltoloxamine
Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form...
Approved
Matched Description: … It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. ... It also potentiates the effects of other drugs, such as codeine and codeine derivatives. ... Phenyltoloxamine acts as an adjuvant analgesic, which augments the analgesic effect of acetaminophen. …
Mobocertinib
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Description: … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion ... [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant ... Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of …
Milrinone
Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart...
Approved
Matched Description: … Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. ... Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure ... second-generation bipyridine phosphodiesterase (PDE) inhibitor created through chemical modification of …
Erlotinib
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... of patients with idiopathic myelofibrosis or essential thrombocythemia. …
Terbutaline
Terbutaline was first synthesized in 1966 and described in the literature in the late 1960s and early 1970s. It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098]
Terbutaline was granted FDA approval on 25 March 1974.
Approved
Levamlodipine
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both...
Approved
Investigational
Matched Description: … [L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. ... Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], …
Agalsidase beta
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Description: … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after …
Estazolam
A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Approved
Illicit
Avapritinib
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a...
Approved
Investigational
Matched Description: … [A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant ... Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived ... growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal …
Agalsidase alfa
Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Description: … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after …
Oritavancin
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Description: … of [vancomycin] therapy. ... Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. ... [A39384,A193482,L8492]
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in …
Hydralazine
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a...
Approved
Matched Description: … hypertension and only as adjunct therapy in the treatment of heart failure. ... Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of ... L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of …
Guanfacine
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Approved
Investigational
Matched Description: … ,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of ... hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD. …
Latanoprostene bunod
Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure.
As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle...
Approved
Investigational
Matched Description: … The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from ... Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, ... ), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma or …
Salmeterol
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Description: … long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of ... [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 …
Betahistine
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.[A220318,L16408]
Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to...
Approved
Investigational
Matched Description: … It has a significant impact on both the physical and social functioning of affected individuals. ... Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing ... was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of …
Displaying drugs 501 - 525 of 8253 in total